Literature DB >> 22691649

Outcomes of arthroscopic double-bundle PCL reconstruction using the LARS artificial ligament.

Chao-Ping Chen1, Yu-Min Lin, Yung-Cheng Chiu, Hong-Wen Wu, Cheng-Hung Lee, Kwok-Man Tong, Kui-Chou Huang.   

Abstract

The purpose of this study was to assess the outcomes of posterior cruciate ligament (PCL) reconstruction using the Ligament Augmentation and Reconstruction System (LARS) (JK Orthomedic Ltd, Dollard-des-Ormeaux, Quebec, Canada) artificial ligament. Compared with older artificial ligaments, the LARS, which has been used in Europe for 15 years, is more resistant to wear and tear, has satisfactory torsional fatigue resistance, and has good biocompatibility. The current is study included 38 double-bundle PCL reconstructions using the LARS artificial ligament in 38 patients. Mean patient age was 32.6 years, and mean time from injury to surgery was 6 months. Mean follow-up was 37 months (range, 30-68 months). The study endpoint was 2-year follow-up. Mean Tegner score improved from 3.4 ± 0.6 preoperatively to 6.0 ± 1.4 postoperatively (P<.001), and mean Lysholm score improved from 70.0 ± 11.0 pre-operatively to 91.7 ± 5.5 postoperatively (P<.001). Knee laxity decreased significantly postoperatively (P<.001), and no differences existed at 1- and 2-year follow-up. After surgery using the Y-type LARS artificial ligament, knee function and stability improved. Using the LARS artificial ligament for double-bundle reconstruction of the PCL avoids donor-site morbidity and disease transmission. The complication rate is low, and the results appear to be stable with time and comparable with those obtained with other grafts. Double-bundle PCL reconstruction with the LARS artificial ligament may be an alternative treatment option. Copyright 2012, SLACK Incorporated.

Entities:  

Mesh:

Year:  2012        PMID: 22691649     DOI: 10.3928/01477447-20120525-16

Source DB:  PubMed          Journal:  Orthopedics        ISSN: 0147-7447            Impact factor:   1.390


  7 in total

1.  Anterior cruciate ligament reconstruction with LARS™ artificial ligament results at a mean follow-up of eight years.

Authors:  Paolo Domenico Parchi; Ciapini Gianluca; Lorenzo Dolfi; Alessandro Baluganti; Piolanti Nicola; Fabio Chiellini; Michele Lisanti
Journal:  Int Orthop       Date:  2013-06-29       Impact factor: 3.075

2.  Three intrasubstance failures of a LARS™ ligament used for ligament reconstruction.

Authors:  V Ramsingh; A D Yewlett; H C Pullen
Journal:  Ann R Coll Surg Engl       Date:  2019-01-03       Impact factor: 1.891

Review 3.  Operative management of isolated posterior cruciate ligament injuries improves stability and reduces the incidence of secondary osteoarthritis: a systematic review.

Authors:  Wouter Schroven; G Vles; J Verhaegen; M Roussot; J Bellemans; S Konan
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2021-09-10       Impact factor: 4.342

4.  Global variation in isolated posterior cruciate ligament reconstruction.

Authors:  Derrick M Knapik; Varun Gopinatth; Garrett R Jackson; Jorge Chahla; Matthew V Smith; Matthew J Matava; Robert H Brophy
Journal:  J Exp Orthop       Date:  2022-10-09

5.  Single versus double bundle in posterior cruciate ligament (PCL) reconstruction: a meta-analysis.

Authors:  Filippo Migliorini; Andrea Pintore; Filippo Spiezia; Francesco Oliva; Frank Hildebrand; Nicola Maffulli
Journal:  Sci Rep       Date:  2022-03-09       Impact factor: 4.379

6.  Hamstring, bone-patellar tendon-bone, quadriceps and peroneus longus tendon autografts for primary isolated posterior cruciate ligament reconstruction: a systematic review.

Authors:  Filippo Migliorini; Andrea Pintore; Gianluca Vecchio; Francesco Oliva; Frank Hildebrand; Nicola Maffulli
Journal:  Br Med Bull       Date:  2022-07-09       Impact factor: 5.841

7.  Ligament Advanced Reinforcement System (LARS) synthetic graft for PCL reconstruction: systematic review and meta-analysis.

Authors:  Filippo Migliorini; Andrea Pintore; Gianluca Vecchio; Francesco Oliva; Frank Hildebrand; Nicola Maffulli
Journal:  Br Med Bull       Date:  2022-09-22       Impact factor: 5.841

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.